Marine-Derived Compounds Applied in Infectious Diseases

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (31 December 2020) | Viewed by 6331

Special Issue Editors


E-Mail Website
Guest Editor
Korea Institute of Ocean Science and Technology (KIOST), Busan, Republic of Korea
Interests: marine natural products; biomedical applications; drug discovery; anticancer compounds; anti-inflammatory compounds; antimicrobial compounds
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Marine Biomedical Sciences, Hanseo University, Chungcheongman-do 31962, Korea
Interests: oxidative stress; antioxidant activity; hepatic inflammation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Infectious diseases are disorders caused by organisms, such as bacteria, viruses, fungi or parasites. Considering the emerging and re-emerging infectious diseases and issues relative to drug resistance, marine organisms are a rich source of novel bioactive leads for the discovery of next-generation antibiotics and/or agents for infectious diseases. There is an urgent need to develop new drugs against viral and bacterial diseases. In particular, the lack of new antibiotics and increase in bacterial resistance to drug treatments needs to be addressed, demanding novel approaches to drug discovery.

Potential topics include but are not limited to the following:

Use of marine bioactive compounds for the treatment/prevention of infectious pathologies

  • Foods originated marine with antifungal/antibacterial capable of ameliorating infective symptoms
  • Theoretical and computational studies of marine bioactive compounds against infectious diseases
  • Pharmacological and toxicological effects of marine bioactive compounds: in vitro and in vivo studies of infectious diseases
  • Clinical or preclinical studies showing marine bioactive compounds properties in the treatment of infectious diseases
  • Technological strategies used to enhance the effects of marine bioactive compounds against infectious diseases.

As a Guest Editor for this Special Issue of Marine Drugs, I cordially invite you to submit original research papers or reviews on the isolation and structure determination, synthesis, and evaluation of novel compounds against bacterial, viral, and fungal diseases, the identification of novel biological targets or therapeutic approaches, or studies about resistance mechanisms and strategies to circumvent them.

Prof. Dr. Hee Jae Shin
Prof. Dr. Seon-Heui Cha
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • infectious diseases
  • marine organisms
  • marine natural products
  • novel therapeutic agents
  • bioactive compounds
  • antimicrobial
  • antifungal
  • antiviral
  • anti-protozoal

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 1686 KiB  
Article
Two New Phomaligols from the Marine-Derived Fungus Aspergillus flocculosus and Their Anti-Neuroinflammatory Activity in BV-2 Microglial Cells
by Byeoung-Kyu Choi, Duk-Yeon Cho, Dong-Kug Choi, Phan Thi Hoai Trinh and Hee Jae Shin
Mar. Drugs 2021, 19(2), 65; https://doi.org/10.3390/md19020065 - 27 Jan 2021
Cited by 6 | Viewed by 2352
Abstract
Two new phomaligols, deketo-phomaligol A (1) and phomaligol E (2), together with six known compounds (38) were isolated from the culture broth of the marine-derived fungus Aspergillus flocculosus. Compound 1 was first isolated as [...] Read more.
Two new phomaligols, deketo-phomaligol A (1) and phomaligol E (2), together with six known compounds (38) were isolated from the culture broth of the marine-derived fungus Aspergillus flocculosus. Compound 1 was first isolated as a phomaligol derivative possessing a five-membered ring. The structures and absolute configurations of the new phomaligols were determined by detailed analyses of mass spectrometry (MS), nuclear magnetic resonance (NMR) data, optical rotation values and electronic circular dichroism (ECD). In addition, the absolute configurations of the known compounds 3 and 4 were confirmed by chemical oxidation and comparison of optical rotation values. Isolated compounds at a concentration of 100 μM were screened for inhibition of nitric oxide (NO) production in lipopolysaccharide (LPS)-induced BV-2 microglial cells. Among the compounds, 4 showed moderate anti-neuroinflammatory effects with an IC50 value of 56.6 μM by suppressing the production of pro-inflammatory mediators in activated microglial cells without cytotoxicity. Full article
(This article belongs to the Special Issue Marine-Derived Compounds Applied in Infectious Diseases)
Show Figures

Figure 1

19 pages, 7766 KiB  
Article
Effects of Chitosan–Gentamicin Conjugate Supplement on Non-Specific Immunity, Aquaculture Water, Intestinal Histology and Microbiota of Pacific White Shrimp (Litopenaeus vannamei)
by Fengyan Liang, Chengpeng Li, Tingting Hou, Chongqing Wen, Songzhi Kong, Dong Ma, Chengbo Sun and Sidong Li
Mar. Drugs 2020, 18(8), 419; https://doi.org/10.3390/md18080419 - 10 Aug 2020
Cited by 20 | Viewed by 3518
Abstract
When the aquaculture water environment deteriorates or the temperature rises, shrimp are susceptible to viral or bacterial infections, causing a large number of deaths. This study comprehensively evaluated the effects of the oral administration of a chitosan–gentamicin conjugate (CS-GT) after Litopenaeus vannamei were [...] Read more.
When the aquaculture water environment deteriorates or the temperature rises, shrimp are susceptible to viral or bacterial infections, causing a large number of deaths. This study comprehensively evaluated the effects of the oral administration of a chitosan–gentamicin conjugate (CS-GT) after Litopenaeus vannamei were infected with Vibrio parahaemolyticus, through nonspecific immunity parameter detection, intestinal morphology observation, and the assessment of microbial flora diversification by 16S rRNA gene sequencing. The results showed that the oral administration of CS-GT significantly increased total hemocyte counts and reduced hemocyte apoptosis in shrimp (p < 0.05). The parameters (including superoxide dismutase, glutathione peroxidase, glutathione, lysozyme, acid phosphatase, alkaline phosphatase, and phenoloxidase) were significantly increased (p < 0.05). The integrity of the intestinal epithelial cells and basement membrane were enhanced, which correspondingly alleviated intestinal injury. In terms of the microbiome, the abundances of Vibrio (Gram-negative bacteria and food-borne pathogens) in the water and gut were significantly reduced. The canonical correspondence analysis (CCA) showed that the abundances of Vibrio both in the water and gut were negatively correlated with CS-GT dosage. In conclusion, the oral administration of CS-GT can improve the immunity of shrimp against pathogenic bacteria and significantly reduce the relative abundances of Vibrio in aquaculture water and the gut of Litopenaeus vannamei. Full article
(This article belongs to the Special Issue Marine-Derived Compounds Applied in Infectious Diseases)
Show Figures

Graphical abstract

Back to TopTop